New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Revenue to profit Fiscal 2025, year to Dec 31, 2025

It lost $10.5M on $319.7K of revenue: $3277.35 for every $100. What is an income statement?

Revenue to profit, in millions of dollars and as a share of revenue
Revenue0.3100.0%
Cost of revenue−0.1−31.6%
Gross profit0.268.4%
Research & development−0.6−184.0%
Selling, general & admin−2.4−739.9%
Other operating costs−7.7−2414.0%
Operating income−10.5−3269.5%
Other income, net0.0−7.9%
Net income−10.5−3277.4%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue$3.4M$9.9M$9.1M$3.3M$11M$14M$11M$8.7M$0.0B$0.0B
Operating income−$20M−$34M−$37M−$23M−$12M−$58M−$46M−$15M−$1M−$10M
Net income−$20M−$35M−$37M−$24M−$22M−$63M−$46M−$11M−$1.4M−$10M
Net margin (right axis)−603.2%−350.7%−410.7%−721.6%−191.4%−464.3%−411.2%−131.2%−563.4%−3277.4%
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
3.39 9.91 9.10 3.28 11.30 13.60 11.24 8.68 0.26 0.32
Revenue Growth
(15.99%) 192.19% (8.20%) (63.95%) 244.38% 20.36% (17.35%) (22.79%) (97.04%) 24.45%
Gross Profit
0.58 5.09 3.68 0.33 6.26 8.35 6.80 5.55 0.20 0.22
Operating Income
(19.50) (34.39) (36.96) (23.23) (12.46) (57.88) (46.35) (15.38) (1.01) (10.45)
EBT
(20.47) (34.76) (37.38) (23.68) (21.81) (63.42) (46.59) (11.33) (1.45) (10.48)
Income after Tax
(20.47) (34.76) (37.38) (23.68) (21.63) (63.15) (46.21) (11.39) (1.45) (10.48)
Net Income Common
(20.47) (34.76) (37.38) (23.68) (21.63) (63.15) (46.21) (11.39) (1.45) (10.26)
EPS (Diluted)
(4.85) (2.08) (19.63) (5.03) (5.54) (1,453,488.00) — (11,104.65) (6,001.39) (4.86)
Shares (Diluted, Weighted)
4.22 16.72 1.90 4.71 3.91 0.00 0.00 0.00 0.00 2.16
Gross Margin
17.21% 51.29% 40.41% 10.09% 55.42% 61.38% 60.52% 63.93% 75.91% 68.44%
EBIT Margin
(574.86%) (346.89%) (406.16%) (708.02%) (110.25%) (425.60%) (412.38%) (177.26%) (391.71%) (3,269.50%)
Net Profit Margin
(603.21%) (350.67%) (410.72%) (721.61%) (191.43%) (464.31%) (411.16%) (131.22%) (563.45%) (3,209.88%)
Free Cash Flow Margin
(581.20%) (319.42%) (337.48%) (702.83%) (79.12%) (115.64%) (195.68%) (195.55%) (238.93%) (1,172.63%)
EBITDA
(19.12) (34.00) (36.40) (22.27) (9.09) (55.42) (44.20) (15.23) (0.99) (10.44)
EBIT
(19.50) (34.39) (36.96) (23.23) (12.46) (57.88) (46.35) (15.38) (1.01) (10.45)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026